{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:34:28Z","timestamp":1786988068308,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ejmech.2023.115214","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T12:24:14Z","timestamp":1677241454000},"page":"115214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Discovery of a novel oral type \u2160 CDK8 inhibitor against acute myeloid leukemia"],"prefix":"10.1016","volume":"251","author":[{"given":"Xing Xing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao Yao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cen Cen","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen Dan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7984-2977","authenticated-orcid":false,"given":"Xin Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115214_bib1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4252\/wjsc.v6.i4.473","article-title":"Identification and targeting leukemia stem cells: the path to the cure for acute myeloid leukemia","volume":"6","author":"Zhou","year":"2014","journal-title":"World J. Stem Cell."},{"key":"10.1016\/j.ejmech.2023.115214_bib2","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.3390\/cancers11122043","article-title":"A novel inhibitor of STAT5 signaling overcomes chemotherapy resistance in myeloid leukemia cells","volume":"11","author":"Brachet-Botineau","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2023.115214_bib3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of relapsed acute myeloid leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.ejmech.2023.115214_bib5","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjh.17746","article-title":"Updates on targeted therapies for acute myeloid leukaemia","volume":"196","author":"Kayser","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2023.115214_bib6","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1007\/s10147-021-02006-7","article-title":"Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed\/refractory acute myeloid leukemia","volume":"26","author":"Hosono","year":"2021","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115214_bib7","doi-asserted-by":"crossref","first-page":"5073","DOI":"10.1021\/acs.jmedchem.7b00901","article-title":"Cyclin-dependent kinase 8: a new hope in targeted cancer therapy?","volume":"61","author":"Philip","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115214_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113043","article-title":"Angel or Devil ? - CDK8 as the new drug target","volume":"213","author":"Wu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115214_bib9","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/nature09590","article-title":"The histone variant macroH2A suppresses melanoma progression through regulation of CDK8","volume":"468","author":"Kapoor","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115214_bib10","doi-asserted-by":"crossref","first-page":"13474","DOI":"10.18632\/oncotarget.24414","article-title":"CDK8\/19 inhibition induces premature G1\/S transition and ATR-dependent cell death in prostate cancer cells","volume":"9","author":"Nakamura","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2023.115214_bib11","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1158\/1078-0432.CCR-16-0094","article-title":"Pan-cancer analysis of the mediator complex transcriptome identifies CDK19 and CDK8 as therapeutic targets in advanced prostate cancer","volume":"23","author":"Br\u00e4gelmann","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115214_bib12","doi-asserted-by":"crossref","first-page":"12095","DOI":"10.1021\/acs.jmedchem.2c00820","article-title":"Discovery of the novel 1H-Pyrrolo[2,3-b]pyridine derivative as a potent type II CDK8 inhibitor against colorectal cancer","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115214_bib13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature07179","article-title":"CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity","volume":"455","author":"Firestein","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115214_bib14","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3390\/cells8080821","article-title":"Identifying cancers impacted by CDK8\/19","volume":"8","author":"Roninson","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2023.115214_bib15","unstructured":"Inhibition of Cdk8 Mediator Kinase S Source Oncotarget So 2017 Jan 29.Pdf>.."},{"key":"10.1016\/j.ejmech.2023.115214_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113248","article-title":"Potent and orally bioavailable CDK8 inhibitors: design, synthesis, structure-activity relationship analysis and biological evaluation","volume":"214","author":"Yu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115214_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113391","article-title":"Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation","volume":"218","author":"Yu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115214_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115461","article-title":"New CDK8 inhibitors as potential anti-leukemic agents - design, synthesis and biological evaluation","volume":"28","author":"Solum","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115214_bib19","doi-asserted-by":"crossref","first-page":"33779","DOI":"10.18632\/oncotarget.16810","article-title":"SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains","volume":"8","author":"Rzymski","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2023.115214_bib20","doi-asserted-by":"crossref","first-page":"8952","DOI":"10.1002\/anie.200904778","article-title":"Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11","volume":"48","author":"Cee","year":"2009","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2023.115214_bib21","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nchembio.1952","article-title":"A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease","volume":"11","author":"Dale","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115214_bib22","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1021\/acs.jmedchem.5b01685","article-title":"Discovery of potent, selective, and orally bioavailable small-molecule modulators of the mediator complex-associated kinases CDK8 and CDK19","volume":"59","author":"Mallinger","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115214_bib23","doi-asserted-by":"crossref","first-page":"9337","DOI":"10.1021\/acs.jmedchem.6b00597","article-title":"Structure-based optimization of potent, selective, and orally bioavailable CDK8 inhibitors discovered by high-throughput screening","volume":"59","author":"Czodrowski","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115214_bib24","doi-asserted-by":"crossref","first-page":"6356","DOI":"10.1021\/acs.jmedchem.1c02190","article-title":"Lessons learned from past cyclin-dependent kinase drug discovery efforts","volume":"65","author":"Xie","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115214_bib25","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41375-017-0005-9","article-title":"Pharmacologic inhibition of STAT5 in acute myeloid leukemia","volume":"32","author":"Wingelhofer","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2023.115214_bib26","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1182\/blood-2008-12-196055","article-title":"FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation","volume":"114","author":"Yoshimoto","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.115214_bib27","first-page":"6710","article-title":"Characteristics of cell lines established from human colorectal carcinoma","volume":"47","author":"Park","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115214_bib28","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.immuni.2012.10.017","article-title":"CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response","volume":"38","author":"Bancerek","year":"2013","journal-title":"Immunity"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423001800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423001800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:46:53Z","timestamp":1759330013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423001800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":27,"alternative-id":["S0223523423001800"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115214","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a novel oral type \u2160 CDK8 inhibitor against acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115214","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115214"}}